Overview
Delayed radiation myelopathy (DRM) is a rare and severe complication arising from radiotherapy, characterized by progressive neurological deficits often due to radiation-induced damage to the spinal cord. 1Diagnosis
Key Diagnostic Criteria: Transverse myelitis pattern on imaging, progressive neurological deficits following radiation therapy.
Recommended Tests: MRI demonstrating residual enhancement in the spinal cord area post-treatment.
Grading: Not explicitly detailed in provided abstracts.Management
First-Line Treatments: Corticosteroids (e.g., methylprednisolone pulse therapy).
Adjunctive Treatments: Intravenous immune globulin (IVIG) considered for potential progression prevention 1.
Other Therapies: Hyperbaric oxygen therapy, anticoagulants, and antivascular endothelial growth factor (VEGF) agents have been explored but lack definitive efficacy 1.Special Populations
Comorbidities: Hypertension may increase the risk of radiation myelopathy 2.Key Recommendations
Initiate corticosteroid therapy (e.g., methylprednisolone pulse therapy) for symptomatic management of delayed radiation myelopathy (Evidence: Moderate 1).
Consider dose limitations to 4400 rad in the thoracic region and reduce by approximately 10% for cervical regions to minimize risk (Evidence: Weak 2).
Monitor patients with hypertension closely due to increased risk of radiation myelopathy (Evidence: Expert opinion 2).References
1 Naghavi S, Motahharynia A, Fatemi F, Ahmadi E, Mokhtari F, Adibi I. The benefit of intravenous immune globulin in the treatment of delayed radiation myelopathy. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2024. link
2 Glanzmann C, Aberle HG, Horst W. The risk of chronic progressive radiation myelopathy. Strahlentherapie 1976. link